

Dr Bayju Thakar, CEO & Dan Curran, CFO

Investor Presentation: Apr 2022

27 April 2022



The market opportunity for Doctor Care Anywhere is enormous



Global Market for Healthcare



US\$10trn

© 2022 Doctor Care Anywhere

Telehealth Markets

Global



US\$144.3bn²

Europe



US\$10.6bn³

Australia



US\$976m⁴

Global telehealth market growth



CAGR 32.8%, 2021-28

Business Overview





Largest private sector provider of digital health services in the UK, conducting over 50,000 VGP consultations per month (>100% growth three years in a row)



Go to market strategy through channel partners covering 2.6m patients. Partners include health insurers and hospitals. Deep technical, operational and cultural integration with channel partners; sticky long term revenue streams



Unique business model that joins up online and offline care; integrating the patient journey across primary and secondary care under a single platform; better patient experience, significant savings for payors, 'ownership' of patient for providers and better margins for DCA



Current product innovation – Health Navigator – will facilitate our ability to scale profitably; becoming the global digital partner of choice



+3x revenue growth potential through existing channel partners in UK alone with very large global growth potential having already entered the Australian market through the acquisition of GP2U/PSYCH2U



2.6m lives



350+ GPs 50+ specialist




250+ staff




1,500+ corporate customers



What we do






















Walgreens Boots Alliance



DOC PROOF POINT

We are solving systemic and global healthcare problems





Significant and growing wait times In the UK; up to 4 weeks in primary care and 18 weeks in secondary care common, even pre-COVID Swift access to primary care (virtual and in person) or onward referral to secondary care at scale through unique operating model





Fragmented health journeys and lack of data integration frustrate patients and clinicians, deliver poorer outcomes and add to costs

Online to offline connected patient journeys. Transparent and joined-up healthcare improves outcomes and reduces costs; one stop shop for patients





Increasing costs for payors. Resulting from waiting times, increased chronicity of disease, ageing populations and lack of standardization of care

Driving claims savings by up to 20% through the combination of our unique operating model and joined-up online to offline journeys



In solving these problems, all stakeholders benefit





Improved Patient journeys

- Faster, easier access to care
- Avoids long waits for appointments, tests and consultations
- Smoother approval process

Better clinical outcomes

- Standardisation of diagnostics
- Latest evidence-based medicine on the platform
- Consistently raising the quality of care through clinical and patient feedback



Differentiation

 Proven cost savings model that drives activity and volume to DCA

Cost savings

- Better control of patient journey
- Smarter procurement
- Fewer unnecessary referrals to specialist and secondary care

Enhanced transparency

 Data transparency and analytics on patient activity and clinical outcomes provide future monetisation opportunities



Convenience and flexibility for Physicians

Operate at time and place of choice

Training and support

 Care team structure provides professional feedback and continuing professional development and ensures quality

Increased income opportunity

• Digital channel

Cost savings

Lower overheads



New revenue stream

- Out of hospital care; both pre and post operative
- Customer ownership; ability to ground build ownership of a patient not just when they are sick

What makes us different



Joined-up online to offline care

Integrated care pathways, joining up journeys across:

- Virtual to in-person
- Primary to secondary care



BENEFITS

- Faster patient journeys
- Better patient outcomes
- Higher levels of patient satisfaction
- Less waste, saving money for health systems



Unique operating model

Technology-driven triage into consultations with a mixed clinical workforce, consulting in variable timeslots across different modalities, depending on patient need



BENEFITS

Drives ability to scale profitably, through overcoming supply / demand mismatch in health systems, through optimising allocation of clinical resource to patient need

Patient journey



In joining up online and offline care across the patient journey we are demonstrating real impact

Traditional UK patient journey







2 + week wait



In person GP consultation



1-6 month Diagnostic wait test



2 week wait



In person GP Consultation



4-6 month wait



Hospital

diagnostic

Specialist



2 week wait



GP and treatment

Our Internet Hospital patient journey



Patient needs a doctor



4-8 hour wait



Virtual GP consultation





3 day wait



Diagnostic test



24 hour wait



Virtual specialist



24 hour wait review



Virtual GP follow up and onward treatment

And is a real point of differentiation for channel partners...

Generating claims savings

Estimate of claims savings due to reduced appts downstream intervention

Retention rates in excess of

c.95%


Satisfying patients

Consistent Net Promoter Score

Roadmap




Our capability roadmap will allow us to scale profitability and make us the partner of choice




Financials





doctor care anywhere.

Eligible lives



Activated Lives






Activates Lives represent the number of users who have 'signed up' for the service and activated their accounts



Marketing and engagement activities are utilized to drive Eligible Lives to activate their accounts




Activated lives key precursor to consultations



anywhere.

Consultations





Consultations represent the number of virtual GP consultations delivered to patients



Consultations are the key driver of revenue growth



Structural factors in UK health system driving sustained demand for services

doctor care anywhere.

Secondary care journeys




Secondary care journeys represent number of patients referred from initial GP consultation to diagnostic tests and specialist review



Growth in secondary care journeys key driver of margin enhancement, with high margin diagnostic rebates generated without incremental service costs




Secondary care journeys are key to delivering benefits to partners, lower cost of claims



Revenue







Strong revenue growth trajectory



'Utilisation' revenue represents revenue generated from the delivery of services (GP consultations, specialist reviews) on a 'per use' basis



'Subscription' revenue represents revenue generated from the deliver on a £ per month subscription basis



'Other' revenue comprises one-off payments for technology development and volume-based incentive payments

Positive start to 2022





1Q22 underlying revenue of **£8.6m,** up 95% on pcp



151,900 consultations delivered in 1Q 2022, up 68% on pcp



Annualised revenue run rate of £34.4m, up 95% on pcp



735,100 activated lives in 1Q22, up 48% on pcp



45.5% underlying gross margin, +980bps on 4Q21




103,300 repeat patients in 1Q22, up 97% on pcp

Guidance




17

Company to reach run-rate EBITDA profitability by 1H FY23 end



- Continued organic consultation growth
- Renegotiated key contracts driving enhanced revenue
- FY22 revenue growth of 40-50%



- Renegotiated key contracts driving margin expansion
- New operating model enhancing productivity and margins
- Gross margin to increase to 50-60% by 1H FY23 end

Outlook



Q2

As per pcp, slightly slower growth and incentives for GPs as three-week Easter holiday and May bank holidays (seasonal). Absolute growth and margin improvement expected versus previous year and in line with internal expectations to achieve guidance issued

Q3 & Q4

Growth and margin improvements expected, with Q1 performance providing confidence

Impact of overhead reductions in Q1 and Q2 realised

Long term

Continued multi-year organic growth and diversification as a result of:

- new strategic partnerships
- new contracted opportunities
- growth of mental health services in Australia

The importance to existing partners will continue through the delivery of joined up pathways and reduced claims and we will seek to further extend joining up primary and secondary care across the whole pathway either organically or through acquisitions should they make sense

With significant demand in the UK alone



9m

People in the UK have private medical insurance

1 in 5

Patients in the UK paid for private care in 2021

6m

Patients on waiting list for care in the UK

2

Listed entities operating in the European telehealth market

DOC

Largest, private provider of telehealth consultations in the UK

Significant growth potential across existing book

Eligible Lives at 1Q22 end

2.6m

If Activated Lives reached

1m

and every Activated Life had

2x

consultations a year

annual revenue would be

>£100m



Fully funded and on track to achieve EBITDA profitability by 1H FY23



On track to achieve FY22 revenue

guidance of £35-38 million (A\$66-71 million).



Continued consultation and revenue growth

expected across year to drive towards FY22 guidance



Strong visibility with Q1

annualised revenue run rate of £34.4 million (A\$64.9 million)



Improving operating leverage

in the business demonstrated, QoQ improvements in gross profit (£1.1 million) and contribution (£1.0 million) in excess of revenue growth (£0.7 million)

Questions?





Appendices

Transforming lives through better healthcare



FY 2021 Results



23

£ in millions	FY21	FY20	Variance	%	1H 21	2H 21	Variance	%
Utilisation revenue	21.0	9.0	12.0	133.3%	8.3	12.7	4.4	53.0%
Subscription revenue	1.9	1.8	0.1	5.6%	0.9	1.0	0.1	11.1%
Other revenue	2.0	0.8	1.2	150.0%	2.0	-	(2.0)	(100.0%)
Revenue	25.0	11.6	13.3	114.7%	11.2	13.7	2.5	22.3%
Cost of sales	(14.6)	(5.9)	(8.7)	(147.5%)	(5.4)	(9.1)	(3.7)	(68.5%)
Gross profit	10.4	5.7	4.6	80.7%	5.8	4.6	(1.2)	(20.7%)
Gross profit margin	41.6%	49.1%	(7.5%)		51.8%	33.6%	(18.2%)	
Underlying gross profit margin	36.7%	45.4%	(8.7%)		41.3%	33.6%	(7.7%)	
Operating costs	(5.4)	(3.1)	(2.3)	(74.2%)	(2.4)	(3.0)	(0.6)	(25.0%)
Contribution	5.0	2.6	2.3	88.5%	3.4	1.6	(1.8)	(52.9%)
Contribution margin	20.0%	22.4%	(2.4%)		30.4%	11.7%	(18.7%)	
Underlying contribution margin	13.1%	16.7%	(3.6%)		15.2%	11.7%	(3.5%)	
Sales and marketing	(3.4)	(1.6)	(1.8)	(112.5%)	(1.6)	(1.8)	(0.2)	(12.5%)
Research and development	(4.8)	(2.2)	(2.6)	(118.2%)	(2.2)	(2.7)	(0.5)	(22.7%)
General and administration	(15.4)	(10.4)	(5.0)	(48.1%)	(6.7)	(8.7)	(2.0)	(29.9%)
Other operating income	0.6	6.0	(5.4)	(90.0%)	0.3	0.3	-	-
Share based payment	(1.0)	(2.2)	1.2	54.5%	(0.6)	(0.4)	0.2	33.3%
Non-operating costs	(24.0)	(10.4)	(13.6)	(130.8%)	(10.8)	(13.3)	(2.5)	(23.1%)
Share of JV net loss	(0.1)	(0.8)	0.7	87.5%	(0.1)	0.1	0.2	200.0%
EBITDA	(19.1)	(8.6)	(10.6)	(123.3%)	(7.5)	(11.6)	(4.1)	(54.7%)
Depreciation and amortisation	(1.3)	(0.9)	(0.4)	(44.4%)	(0.5)	(0.8)	(0.3)	(60.0%)
EBIT	(20.4)	(9.5)	(11.0)	(115.8%)	(8.0)	(12.4)	(4.4)	(55.0%)



Underlying contribution margin (%)

Eligible lives at period end (in 000s)

Utilisation – eligible lives at period end (in 000s)

Subscription – eligible lives at period end (in 000s)

Utilisation – activated lives at period end (in 000s)

Subscription – activated lives at period end (in 000s)

1Q 2022

27.8%

2,395.3

172.5

2,567.8

680.2

54.9



1Q 2021 %

9.2%

(6.8%)

8.0%

51.2%

18.8%

Variance

PCP

780bps

202.6

(12.5)

190.1

230.4

8.7

1Q 2021

20.0%

2,192.7

185.0

2,377.7

449.8

46.2

Revenue (£ in millions)	8.6	7.9	0.7	8.9%	6.4	2.2	34.4%
Gross profit margin (%)	45.5%	35.7%	980bps		60.7%	(1,520bps)	
Contribution margin (%)	27.8%	17.4%	1,040bps		44.6%	(1,680bps)	
Underlying revenue (£ in millions)	8.6	7.9	0.7	8.9%	4.4	4.2	95.5%
Underlying gross profit (£ in millions)	3.9	2.8	1.1	39.3%	1.9	2.0	105.3%
Underlying contribution (£ in millions)	2.4	1.4	1.0	71.4%	0.9	1.5	166.7%
Underlying gross profit margin (%)	45.5%	35.7%	980bps		43.2%	230bps	
	 	 					

17.4%

2,299.3

140.4

2,439.7

621.9

53.1

4Q 2021

Variance

4Q 2021 %

4.2%

22.9%

5.3%

9.4%

3.4%

Q on Q

1,040bps

96.0

32.1

128.1

58.3

1.8





25

Variance	Variance
----------	----------

	1Q 2022	4Q 2021	Q on Q	4Q 2021 %	1Q 2021	РСР	1Q 2021 %
Activated lives at period end (in 000s)	735.1	675.0	60.1	8.9%	496.0	239.1	48.2%
Utilisation - activation % (at period end)	28.4%	27.0%	140bps		20.5%	790bps	
Subscription – activation % (at period end)	31.8%	37.8%	(600bps)		24.9%	690bps	
Activation % (at period end)	28.6%	27.7%	90bps		20.9%	770bps	
Utilisation – average activated lives (in 000s)	664.8	616.5	48.3	7.8%	427.0	237.8	55.7%
Subscription – average activated lives (in 000s)	54.2	51.5	2.7	5.2%	45.9	8.3	18.1%
Average activated lives (in 000s)	719.0	668.0	51.0	7.6%	472.9	246.1	52.0%
Utilisation – consultations (in 000s)	136.4	123.6	12.8	10.4%	84.2	52.2	62.0%
Subscription – consultations (in 000s)	8.1	8.3	(0.2)	(2.4%)	6.4	1.7	26.6%
Other – consultations (in 000s)	7.4	11.4	(0.4)	(3.5%)	-	7.4	-
Consultations (in 000s)	151.9	143.3	8.5	5.9%	90.6	61.3	67.7%
Utilisation – annualised utilisation (%)	82.0%	80.2%	180bps		78.8%	320bps	
Subscription – annualised utilisation (%)	60.1%	64.4%	(430bps)		55.6%	450bps	
Annualised utilisation (%)	80.4%	79.0%	140bps		76.6%	380bps	



